Gilead Seals VLs For Lenacapavir Amid Concerns Around Price, API Supplies

Gilead strikes voluntary licensing agreements with six generic manufacturers for lenacapavir but health groups seek clarity on pricing and seeming API supply restrictions. All eyes are also on the patent opposition case in India.

Gilead Sciences, Inc.’s voluntary licensing (VL) agreements for lenacapavir may have managed to take some of the sting out of the patent opposition case in India but health groups and activists don’t seem to be backing off.

They have now also flagged up apparent restrictions around supplies of active pharmaceutical ingredients (APIs) in the VL arrangements, which...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Biogen’s Spinraza Follow-On May Offer Disease-Modifying Potential

25 Jun 2025

• By Joseph Haas

Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.

Kymera Inks CDK2 Deal With Gilead

25 Jun 2025

• By Alaric DeArment

Deal Snapshot: The biotech will receive up to $750m from Gilead for molecular glue degraders against CDK2.

Nektar Bounces Back As Eczema Drug Rezpeg Heads For Phase III

25 Jun 2025

• By Kevin Grogan

Lilly-rejected candidate impresses in Phase IIb atopic dermatitis trial.

Battle For Obesity Market Shifts Gears in India: Will Wegovy Trump Mounjaro?

25 Jun 2025

• By Anju Ghangurde

Novo Nordisk debuts Wegovy in India, gears for pole position in obesity. The Danish group’s leadership doesn’t appear too perturbed about the head start for Lilly’s Mounjaro or the imminent arrival of generic semaglutide next year.